Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Forward Pharma

Evaluate

Thumbnail
April 10, 2018

Where is the IPO class of 2014-15 now?

A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.

Thumbnail
January 30, 2018

Biogen burned as Forward goes backwards

Biogen might be wondering what else it could have spent $1.2bn on as Forward Pharma's patent challenge against Tecfidera falters.

Article image
Vantage logo
January 08, 2018

Asia wins 2017’s mid-cap race

A cooling of the M&A climate allows Asia-based groups to come to the fore.

Vantage logo
November 28, 2017

Alkermes’s Tecfidera sleeper falls asleep

Vantage logo
September 18, 2017

Corrected: Weekly Market Movers: Global Majors & Industry (to 15 Sep 2017)

Vantage logo
April 03, 2017

Patent rulings knock Acorda and Forward | News

Article image
Vantage logo
April 03, 2017

Patent rulings knock Acorda and Forward

Acorda and Forward have been bashed by unfavourable US patent verdicts in multiple sclerosis, while Steadymed got a boost.

Vantage logo
March 31, 2017

Snippet roundup: Novartis meets CAR-T filing deadline, Numab snares Ono

Vantage logo
March 22, 2017

Court victory benefits Biogen and its Tecfidera rival alike

Vantage logo
January 17, 2017

Biogen windfall reveals Europe's best capitalised and most mispriced biotech

Vantage logo
November 14, 2016

Event – Biogen gears up for Tecfidera’s day in patent court

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up